Kathryn R Tringale, Christian Grommes, Burcin Agridag Ucpinar, Anne S Reiner, Joachim Yahalom, Gustav Cederquist, Lauren Schaff, Vaios Hatzoglou, Robert J Young, Mousa Payinkay, Grace Bartlett, Michael Scordo, Brandon S Imber, Javin Schefflein
{"title":"Consolidation Regimen and Cerebral Atrophy in Patients with Primary Central Nervous System Lymphoma.","authors":"Kathryn R Tringale, Christian Grommes, Burcin Agridag Ucpinar, Anne S Reiner, Joachim Yahalom, Gustav Cederquist, Lauren Schaff, Vaios Hatzoglou, Robert J Young, Mousa Payinkay, Grace Bartlett, Michael Scordo, Brandon S Imber, Javin Schefflein","doi":"10.1016/j.ijrobp.2024.11.088","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>In primary central nervous system lymphoma (PCNSL), the extent to which post-methotrexate consolidation contributes to neurotoxicity is unclear. Concerns for neurotoxicity from standard-dose whole-brain radiotherapy (WBRT) have led to declining use. Cerebral atrophy is an established surrogate for neurotoxicity; however, the relative extent to which modern consolidation (i.e., reduced-dose [RD-]WBRT £24Gy, autologous hematopoietic cell transplant [AHCT]) contributes to cerebral atrophy is unclear.</p><p><strong>Methods: </strong>Patients with PCNSL from 2000-2020 who achieved complete response to consolidation following MTX-based induction were included. Inclusion criteria were pre-consolidation MRI (baseline) and ≥1 MRI showing sustained remission at 1, 3, 5, or 10 years. An expert neuroradiologist longitudinally measured parenchymal volume loss via ventricular volumetric change. Linear mixed effects models were performed to estimate absolute and annual volumetric change rates.</p><p><strong>Findings: </strong>Of 139 patients (median follow-up 4.5 years), most were XXXX Center Recursive Partitioning Analysis (RPA) class 2 (age ≥50, Karnofsky performance score [KPS] ≥70). Consolidation therapies included non-myeloablative chemotherapy (n=57; 41%), high-dose myeloablative chemotherapy with AHCT (n=50; 36%), and RD-WBRT (n=28; 20%). Higher RPA class was associated with greater baseline ventricular volume (p<0.001). Overall adjusted annual ventricular volume change rates were greater than those published in healthy controls (4.3% vs. 1.8%) and generally increased by age/decade at diagnosis: 40-49-year-olds 1.8% (95%CI: -1.4%, 5.0%), 50-59-year-olds 3.1% (95%CI: 0.7%, 5.5%), 60-69-year-olds 4.8% (95%CI: 2.4%, 7.3%), 70-79-year-olds 7.2% (95%CI: 4.3%, 10.2%), and 80-89-year-olds 4.2% (95%CI: -1.1%, 9.6%). There were no significant associations between consolidation strategy and ventricular volume change rates accounting for age, KPS, gender, baseline ventricular volume, or interaction between age and consolidation.</p><p><strong>Interpretation: </strong>These findings demonstrate accelerated cerebral atrophy in PCNSL after consolidation compared to healthy adults. However, atrophy did not differ by consolidation strategy. These long-term results suggest acceptable neurotoxicity following RD-WBRT.</p>","PeriodicalId":14215,"journal":{"name":"International Journal of Radiation Oncology Biology Physics","volume":" ","pages":""},"PeriodicalIF":6.4000,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Radiation Oncology Biology Physics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ijrobp.2024.11.088","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: In primary central nervous system lymphoma (PCNSL), the extent to which post-methotrexate consolidation contributes to neurotoxicity is unclear. Concerns for neurotoxicity from standard-dose whole-brain radiotherapy (WBRT) have led to declining use. Cerebral atrophy is an established surrogate for neurotoxicity; however, the relative extent to which modern consolidation (i.e., reduced-dose [RD-]WBRT £24Gy, autologous hematopoietic cell transplant [AHCT]) contributes to cerebral atrophy is unclear.
Methods: Patients with PCNSL from 2000-2020 who achieved complete response to consolidation following MTX-based induction were included. Inclusion criteria were pre-consolidation MRI (baseline) and ≥1 MRI showing sustained remission at 1, 3, 5, or 10 years. An expert neuroradiologist longitudinally measured parenchymal volume loss via ventricular volumetric change. Linear mixed effects models were performed to estimate absolute and annual volumetric change rates.
Findings: Of 139 patients (median follow-up 4.5 years), most were XXXX Center Recursive Partitioning Analysis (RPA) class 2 (age ≥50, Karnofsky performance score [KPS] ≥70). Consolidation therapies included non-myeloablative chemotherapy (n=57; 41%), high-dose myeloablative chemotherapy with AHCT (n=50; 36%), and RD-WBRT (n=28; 20%). Higher RPA class was associated with greater baseline ventricular volume (p<0.001). Overall adjusted annual ventricular volume change rates were greater than those published in healthy controls (4.3% vs. 1.8%) and generally increased by age/decade at diagnosis: 40-49-year-olds 1.8% (95%CI: -1.4%, 5.0%), 50-59-year-olds 3.1% (95%CI: 0.7%, 5.5%), 60-69-year-olds 4.8% (95%CI: 2.4%, 7.3%), 70-79-year-olds 7.2% (95%CI: 4.3%, 10.2%), and 80-89-year-olds 4.2% (95%CI: -1.1%, 9.6%). There were no significant associations between consolidation strategy and ventricular volume change rates accounting for age, KPS, gender, baseline ventricular volume, or interaction between age and consolidation.
Interpretation: These findings demonstrate accelerated cerebral atrophy in PCNSL after consolidation compared to healthy adults. However, atrophy did not differ by consolidation strategy. These long-term results suggest acceptable neurotoxicity following RD-WBRT.
期刊介绍:
International Journal of Radiation Oncology • Biology • Physics (IJROBP), known in the field as the Red Journal, publishes original laboratory and clinical investigations related to radiation oncology, radiation biology, medical physics, and both education and health policy as it relates to the field.
This journal has a particular interest in original contributions of the following types: prospective clinical trials, outcomes research, and large database interrogation. In addition, it seeks reports of high-impact innovations in single or combined modality treatment, tumor sensitization, normal tissue protection (including both precision avoidance and pharmacologic means), brachytherapy, particle irradiation, and cancer imaging. Technical advances related to dosimetry and conformal radiation treatment planning are of interest, as are basic science studies investigating tumor physiology and the molecular biology underlying cancer and normal tissue radiation response.